Gymnema sylvestre as a potential therapeutic agent for PCOS: insights from mRNA differential gene expression and molecular docking analysis

Future Journal of Pharmaceutical Sciences

Table 7 Toxicity analysis of promising phytocompounds

PubChem CID	hERG	DILI	Ames	FDAMMD	CG	IGC50	LC50	NR-AR	NR-ER	NR-PPAR-gamma
259846	0.034	0.018	0.015	0.845	0.009	5.481	6.898	0.002	0.298	0.009
73145	0.004	0.008	0.018	0.715	0.017	5.442	6.786	0.005	0.3	0.094
6918391	0.027	0.013	0.007	0.718	0.146	3.963	4.793	0.016	0.091	0.005
5280794	0.012	0.055	0.029	0.539	0.054	4.978	5.511	0	0.369	0.005
15560302	0.008	0.007	0.027	0.824	0.044	4.54	5.131	0.031	0.119	0.572
9548714	0.078	0.051	0.016	0.554	0.007	5.603	6.69	0.001	0.378	0.006

hERG: The human ether-a-go-go related gene; DILI: Drug-induced liver injury; AMES: The Ames test for mutagenicity; FDAMMD: maximum recommended daily dose; CG: Carcinogenicity; IGC50: Tetrahymena pyriformis 50 per cent growth inhibition concentration; LC50: 96-h fathead minnow LC₅₀; NR-AR: Androgen receptor; NR-AR: Oestrogen receptor; NR-PPAR-gamma: Peroxisome proliferator-activated receptor gamma